Posts

The developmental origins of resistant infant leukaemia

The Roy and Milne labs are investigating the developmental origins of infant leukaemia and its influence on the biology of the disease

Understanding clonal haematopoiesis for COVID and cancer

Prof Paresh Vyas and team have been investigating how a better understanding of clonal haematopoiesis can be applied to both cancer and to care of COVID patients

Helping blood cancer patients in the COVID era

The Oxford-led UK Coronavirus Cancer Monitoring Project was launched earlier this year to help clinicians better treat blood cancer patients in a safe way during the COVID-pandemic

Tackling blood cancers in Tanzania and Uganda

Scientists from Tanzania, Uganda and Oxford University have teamed up in a new child blood cancer program

Balancing the benefits and risks of radiotherapy for Hodgkin lymphoma

Dr Rebecca Shakir is devising a tool to allow some blood cancer patients to make more informed decisions about the risks and benefits of their radiotherapy treatment

Harnessing immune cell therapy in cancer

Prof Paresh Vyas and his team are investigating how to harness the power of T cells as therapies for patients with a range of blood cancers

The impact of COVID-19 on cancer patients

A new study from the UK Coronavirus Cancer Monitoring Project (UKCCMP) has investigated which cancer patients may be more susceptible to the impacts of coronavirus

Oxford lymphoid study group established

The new Oxford Lymphoid Disorder Study Group, chaired by Dr Graham Collins, will be launched this September in Blood Cancer Awareness Month

TP53 gene determines severe blood cancer development

A new study has found that the allelic appearance of the TP53 gene has great impact on development of severe types of blood cancer

Prof Anna Schuh wins Vice-Chancellor Innovation Award

Anna and her team wins the Teamwork award for their work on improving the outcome of children with blood diseases in sub-Saharan Africa